P Perspective Therapeutics, Inc.: insider trades · United States · SEC (Form 4) Discover the full insider trade history of Perspective Therapeutics, Inc., a listed issuer based in United States. Shares are quoted on US US, under the supervision of SEC (Form 4). Market capitalisation: €378.6m. The latest transaction was filed on 1 April 2025 (Acquisition). Among the most active insiders: Williamson Robert F III. The full history is free.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Last declaration on 1 April 2025
All Executives28 Thresholds0 Prospectus0 Other0
Declarations 28 total
▲ Director · Executives · 31 Mar 2025
23,475 shares @ US$2.1299 19.6% of flow Common Stock SEC:0000950170-25-048691:0
Ideal exit: 26 Dec 2025 (T+270) ▲ Director · Executives · 28 Mar 2025
22,192 shares @ US$2.27 26.0% of flow Common Stock SEC:0000950170-25-048698:0
Ideal exit: 23 Dec 2025 (T+270) ▲ Chief Executive Officer · Executives · 28 Mar 2025
22,026 shares @ US$2.2421 19.4% of flow Common Stock SEC:0000950170-25-048775:0
Ideal exit: 23 Dec 2025 (T+270) ▲ Chief Financial Officer · Executives · 28 Mar 2025
33,333 shares @ US$2.2484 100.0% of flow Common Stock SEC:0000950170-25-048696:0
Ideal exit: 23 Dec 2025 (T+270) ▲ Director · Executives · 4 Dec 2024
25,975 shares @ US$3.85 100.0% of flow Common Stock SEC:0000950170-24-134067:0
Ideal exit: 31 Aug 2025 (T+270) ▲ CEO · Executives · 4 Dec 2024
8,000 shares @ US$3.7665 12.1% of flow Common Stock SEC:0000950170-24-133355:0
Ideal exit: 31 Aug 2025 (T+270) ▲ Chief Financial Officer · Executives · 25 Nov 2024
400 shares @ US$3.55 2.1% of flow Common Stock SEC:0000950170-24-131250:0
Ideal exit: 22 Aug 2025 (T+270) ▲ Director · Executives · 25 Nov 2024
3,647 shares @ US$3.6199 7.0% of flow Common Stock SEC:0000950170-24-131251:0
Ideal exit: 22 Aug 2025 (T+270) ▲ CEO · Executives · 25 Nov 2024
14,500 shares @ US$3.784 22.2% of flow Common Stock SEC:0000950170-24-130754:0
Ideal exit: 22 Aug 2025 (T+270) ▲ Chief Financial Officer · Executives · 17 Jun 2024
1,800 shares @ US$9.815 25.6% of flow Common Stock SEC:0000950170-24-074594:0
Ideal exit: 14 Mar 2025 (T+270) ▲ Director · Executives · 14 Jun 2024
4,504 shares @ US$10.90 19.4% of flow Common Stock SEC:0000950170-24-074592:0
Ideal exit: 11 Mar 2025 (T+270) ▲ CEO · Executives · 13 Jun 2024
100,000 shares @ US$1.1743 46.3% of flow Common Stock SEC:0000950170-24-073145:0
Ideal exit: 10 Mar 2025 (T+270) ▲ Director · Executives · 3 Jun 2024
34,246 shares @ US$1.4598 19.4% of flow Common Stock SEC:0000950170-24-068638:0
Ideal exit: 28 Feb 2025 (T+270) ▲ Chief Financial Officer · Executives · 31 May 2024
13,006 shares @ US$1.3999 26.1% of flow Common Stock SEC:0000950170-24-067953:0
Ideal exit: 25 Feb 2025 (T+270) ▲ Director · Executives · 31 May 2024
55,000 shares @ US$1.38 39.1% of flow Common Stock SEC:0000950170-24-067945:0
Ideal exit: 25 Feb 2025 (T+270) ▲ Director · Executives · 29 May 2024
11,375 shares @ US$1.32 7.8% of flow Common Stock SEC:0000950170-24-066557:0
Ideal exit: 23 Feb 2025 (T+270) ◇ VP Finance/Prin Fin&Acct Offic · Executives · 23 Apr 2024
30,000 shares @ US$0.36 100.0% of flow Common stock SEC:0000950170-24-047645:0
60,431,039 shares @ US$0.95 100.0% of flow Common Stock SEC:0000950170-24-028446:0
Ideal exit: 1 Dec 2024 (T+270) ▲ Director · Executives · 30 Jan 2024
18,579 shares @ US$0.71 6.8% of flow Common Stock SEC:0001437749-24-002837:0
Ideal exit: 26 Oct 2024 (T+270) ▲ Director · Executives · 26 Jan 2024
12,250 shares @ US$0.61 3.8% of flow Common Stock SEC:0001437749-24-002571:0
Ideal exit: 22 Oct 2024 (T+270) ▲ Director · Executives · 24 Jan 2024
29,862 shares @ US$0.49 7.5% of flow Common Stock SEC:0001437749-24-002322:0
Ideal exit: 20 Oct 2024 (T+270) ▲ Chief Medical Officer · Executives · 24 Jan 2024
280,000 shares @ US$0.4996 79.6% of flow Common Stock SEC:0001437749-24-002324:0
Ideal exit: 20 Oct 2024 (T+270) ▲ Director · Executives · 21 Dec 2023
3,663 shares @ US$0.3283 0.6% of flow Common Stock SEC:0001437749-23-035321:0
Ideal exit: 16 Sept 2024 (T+270) ▲ Director · Executives · 18 Dec 2023
10,000 shares @ US$0.26 1.3% of flow Common Stock SEC:0001437749-23-034933:0
Ideal exit: 13 Sept 2024 (T+270) ▲ Chief Medical Officer · Executives · 15 Dec 2023
135,006 shares @ US$0.2687 20.4% of flow Common Stock SEC:0001437749-23-034931:0
Ideal exit: 10 Sept 2024 (T+270) 25 of 28 declarations
Load more (3 remaining)